PT  - JOURNAL ARTICLE
AU  - Guillen-Guio, Beatriz
AU  - Marcelino-Rodriguez, Itahisa
AU  - Lorenzo-Salazar, Jose Miguel
AU  - Leavy, Olivia C
AU  - Allen, Richard J
AU  - ,
AU  - Riancho, José A.
AU  - Rojas, Augusto
AU  - Lapunzina, Pablo
AU  - Carracedo, Ángel
AU  - Wain, Louise V
AU  - Flores, Carlos
TI  - Polygenic risk of idiopathic pulmonary fibrosis and COVID-19 severity
AID  - 10.1101/2023.06.12.23291269
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.06.12.23291269
4099  - http://medrxiv.org/content/early/2023/06/13/2023.06.12.23291269.short
4100  - http://medrxiv.org/content/early/2023/06/13/2023.06.12.23291269.full
AB  - Introduction Coronavirus disease 2019 (COVID-19) survivors can develop residual lung abnormalities consistent with lung fibrosis. A shared genetic component between COVID-19 and idiopathic pulmonary fibrosis (IPF) has been shown. However, genetic overlap studies of IPF and COVID-19 have primarily concentrated on the IPF genome-wide significant risk variants that have been previously identified, rather than combined into a genome-wide polygenic risk. Here we used IPF genome-wide association study (GWAS) results to calculate polygenic risk scores (PRSs) and study their association with COVID-19 severity.Methods We used results from the largest meta-GWAS of clinically defined IPF risk (base dataset; n=24,589) and individual-level imputed data from the SCOURGE study of patients with COVID-19 (target dataset; n=15,024). We calculated IPF PRSs using PRSice-2 and assessed their association with COVID-19 hospitalisation, severe illness, and critical illness. We also evaluated the effect of age and sex stratification. Results were validated using an independent PRS method. Enrichment analyses and pathway-specific PRSs were performed to study biological pathways associated with COVID-19 severity.Results IPF PRSs were significantly associated with COVID-19 hospitalisation and severe illness. The strongest association was found in patients aged <60 years, especially among younger males (OR=1.16; 95%CI=1.08-1.25; p=6.39×10−5). A pathway enrichment analysis of the variants included in the best model fit and subsequent pathway-specific PRSs analyses supported the link of Cadherin and Integrin signalling pathways to COVID-19 severity when stratified by age and sex.Conclusion Our results suggest that there is genome-wide genetic overlap between IPF and severe COVID-19 that is dependent on age and sex and adds further support that the pathogenesis of both IPF and severe COVID-19 share underlying biological mechanisms. This could imply that individuals with a high IPF genetic risk are at an overall increased risk of developing lung sequelae resulting from severe COVID-19.Competing Interest StatementLVW reports research funding from GlaxoSmithKline, Genentech and Orion Pharma, and consultancy for Galapagos and GlaxoSmithKline, outside of the submitted work. The other authors declare no competing interests.Funding StatementBGG is supported by Wellcome Trust grant 221680/Z/20/Z. LVW holds a GlaxoSmithKline Asthma + Lung UK Chair in Respiratory Research (C17-1). The work was funded by Instituto de Salud Carlos III (COV20_00622 to AC, PI20/00876 to CF); European Union (ERDF) "A way of making Europe". Fundacion Amancio Ortega, Banco de Santander (to AC), Agencia Estatal de Investigacion (RTC-2017-6471-1 to CF), Cabildo Insular de Tenerife (CGIEU0000219140 and "Apuestas cientificas del ITER para colaborar en la lucha contra la COVID-19" to CF) and Fundacion Canaria Instituto de Investigacion Sanitaria de Canarias (PIFIISC20/57 to CF). This research was partially supported by the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre; the views expressed are those of the author(s) and not necessarily those of the National Health Service, the NIHR, or the Department of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The SCOURGE study was approved by the Galician Ethical Committee Ref 2020/197. For IPF, we used only openly available human data, which can be obtained from: https://github.com/genomicsITER/PFgenetics.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors